Dose-ranging Study of Tranexamic Acid in Valve Surgery
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Cardiac surgical procedures account for a large amount of allogeneic transfusion. Tranexamic
acid (TA), a synthetic antifibrinolytic drug, has been shown to reduce blood loss and
transfusion requirements in cardiac surgery with Cardiopulmonary bypass. There are currently
multiple dosing regimens for TA in cardiac surgery. Preliminary dose-response study has shown
that low dose of TA would be as hemostatic efficacy as higher dose. Currently, no randomized
study focus on TA in primary valve surgery. The aim of this prospective, double-blinded,
randomized trial is to compare two dosing regimens of TA during primary valve surgery on
perioperative blood loss and allogeneic blood transfusion.
Phase:
N/A
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital